Dimerix Expands Kidney Pipeline With Phase 2-Ready Acquisition
· smallcaps.com.au
Dimerix expands kidney pipeline with DMX-652 acquisition; Phase 2-ready AKI therapy targets US$3.5b market, upfront US$5m plus up to US$292m milestones.
Dimerix (ASX: DXB) has acquired DMX-652 from Mission Therapeutics for all indications, adding a Phase 2-ready candidate initially focused on preventing acute ki...